Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in Br J Dermatol Retrieve available abstracts of 147 articles: HTML format

Single Articles

April 2024
1. NIELSEN JB, Kristiansen IS, Thapa S
   Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?
   Br J Dermatol. 2024 Apr 24:ljae175. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. 
   A novel strategy for the treatment of melanoma.
   Br J Dermatol. 2024;190:e51.
   PubMed    
   
   
   
3. 
   Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
   Br J Dermatol. 2024;190:e58.
   PubMed    
   
   
   
4. JONES OT, Matin RN, Walter FM
   Using artificial intelligence-based technologies to support the diagnosis and early detection of melanoma in primary care.
   Br J Dermatol. 2024 Apr 9:ljae094. doi: 10.1093.
   PubMed    
   
   
   March 2024
5. TALTY R, Richmond R, Micevic G
   Melanoma TIL therapy commences era of cell-based immunotherapies.
   Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.
   PubMed    
   
   
   
6. 
   AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
   Br J Dermatol. 2024;190:e46.
   PubMed    
   
   
   
7. 
   International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
   Br J Dermatol. 2024;190:e40.
   PubMed    
   
   
   February 2024
8. RIBERO S, Quaglino P, Roccuzzo G
   Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
   Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.
   PubMed    
   
   
   
9. EGELER MD, Ryll B
   Survival is not enough: understanding the mental burden of cutaneous melanoma.
   Br J Dermatol. 2024 Feb 3:ljae050. doi: 10.1093.
   PubMed    
   
   
   January 2024
10. MUKHTAR AB, Morgan HJ, Gibbs A, Davies GE, et al
    Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
    Br J Dermatol. 2024 Jan 30:ljad502. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. BERGAMASCHI D
    Improving cancer stem cells killing in malignant melanoma.
    Br J Dermatol. 2024 Jan 29:ljae035. doi: 10.1093.
    PubMed    
    
    
    
12. 
    Risk factors for developing a new primary melanoma in people with a melanoma.
    Br J Dermatol. 2024;190:e15.
    PubMed    
    
    
    
13. 
    Genes associated with nodular melanoma.
    Br J Dermatol. 2024;190:e18.
    PubMed    
    
    
    
14. PAPACHRISTOU P, Soderholm M, Pallon J, Taloyan M, et al
    Evaluation of an artificial intelligence-based decision support for detection of cutaneous melanoma in primary care - a prospective, real-life, clinical trial.
    Br J Dermatol. 2024 Jan 17:ljae021. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. PENA-MARTIN J, Garcia-Ortega MB, Palacios-Ferrer JL, Diaz C, et al
    Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study.
    Br J Dermatol. 2024 Jan 12:ljae013. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. COCCIMIGLIO M, Chiodo F, van Kooyk Y
    The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
    Br J Dermatol. 2024 Jan 10:ljad517. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. KUNGWENGWE G, Gowthorpe C, Ali SR, Warren H, et al
    Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression.
    Br J Dermatol. 2024 Jan 10:ljae011. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
18. 
    Genetics and melanoma screening.
    Br J Dermatol. 2023;190:e4.
    PubMed    
    
    
    
19. EGGERMONT CJ, Eggermont AMM
    Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.
    Br J Dermatol. 2023 Dec 14:ljad480. doi: 10.1093.
    PubMed    
    
    
    November 2023
20. MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
    Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
    Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.
    PubMed    
    
    
    
21. EWEN T, Husain A, Stefanos N, Barrett P, et al
    Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
    Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. KAMMINGA NCW, Wakkee M, Swart I, Nijsten TEC, et al
    Determining the core content of a digital survivorship care plan for melanoma survivors: A multi-stakeholder Delphi-consensus study.
    Br J Dermatol. 2023 Nov 18:ljad450. doi: 10.1093.
    PubMed    
    
    
    
23. DESSINIOTI C, Stratigos AJ
    Decoding the nodular melanoma subtype- what about genetics?
    Br J Dermatol. 2023 Nov 17:ljad445. doi: 10.1093.
    PubMed    
    
    
    
24. 
    Survival trends in people with melanoma in Sweden.
    Br J Dermatol. 2023;189:e108.
    PubMed    
    
    
    
25. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
    Br J Dermatol. 2023 Nov 8:ljad342. doi: 10.1093.
    PubMed    
    
    
    
26. SMIT AK, Cust AE
    Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
    Br J Dermatol. 2023 Nov 6:ljad431. doi: 10.1093.
    PubMed    
    
    
    October 2023
27. OLSEN CM, Pandeya N, Ragaini BS, Neale RE, et al
    International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020.
    Br J Dermatol. 2023 Oct 27:ljad425. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. AUTIER P
    Melanoma incidence and COVID-19 lockdowns in the Netherlands.
    Br J Dermatol. 2023 Oct 4:ljad376. doi: 10.1093.
    PubMed    
    
    
    September 2023
29. STARK MS, Sturm RA, Pan Y, Smit DJ, et al
    Assessing the genetic risk of nodular melanoma using a candidate gene approach.
    Br J Dermatol. 2023 Sep 28:ljad365. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. VAN DOORN R
    Multiple Primary Melanoma: Risk Factors Reviewed.
    Br J Dermatol. 2023 Sep 15:ljad343. doi: 10.1093.
    PubMed    
    
    
    
31. 
    Features of very thin melanoma that predict lymph node involvement.
    Br J Dermatol. 2023;189:e74.
    PubMed    
    
    
    
32. GUERRERO-JUAREZ CF, Goyal PK, Amber KT
    Targeting IL-4/IL-13 in immune checkpoint inhibitor induced bullous pemphigoid: a cautionary note on the beneficial effect of Th2 in melanoma and immunotherapy.
    Br J Dermatol. 2023 Sep 13:ljad324. doi: 10.1093.
    PubMed    
    
    
    
33. PANDEYA N, Dusingize JC, Olsen CM, MacGregor S, et al
    Does genetic risk modify the effect of skin screening on melanoma detection rates?
    Br J Dermatol. 2023 Sep 8:ljad333. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2023
34. 
    Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
    Br J Dermatol. 2023 Aug 24:ljad288. doi: 10.1093.
    PubMed    
    
    
    
35. 
    Validation of a blood test for melanoma.
    Br J Dermatol. 2023;189:e65.
    PubMed    
    
    
    
36. CLAESON M
    Real-world data show improved melanoma survival in Sweden.
    Br J Dermatol. 2023 Aug 24:ljad309. doi: 10.1093.
    PubMed    
    
    
    
37. SMITH J, Cust AE, Lo SN
    Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis.
    Br J Dermatol. 2023 Aug 10:ljad275. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2023
38. PAN CX, Kim DY, Lau CB, Lau WC, et al
    Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: A retrospective cohort study.
    Br J Dermatol. 2023 Jul 28:ljad271. doi: 10.1093.
    PubMed    
    
    
    
39. VIKSTROM S, Mikiver R, Lapins J, Nielsen K, et al
    Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
    Br J Dermatol. 2023 Jul 18:ljad244. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    PubMed     Abstract available
    
    
    
41. GIUFFRIDA R, Zanin Poletto G, Guarneri F, Conforti C, et al
    Nevus count on the face for the identification of patients with higher risk of melanoma.
    Br J Dermatol. 2023 Jul 6:ljad216. doi: 10.1093.
    PubMed    
    
    
    
42. RIBERO S, Quaglino P, Roccuzzo G
    Predicting progression in very thin melanoma: the challenge of the next decade?
    Br J Dermatol. 2023 Jul 3:ljad218. doi: 10.1093.
    PubMed    
    
    
    June 2023
43. KAKISH H, Sun J, Zheng DX, Ali Ahmed F, et al
    Predictors of Sentinel Lymph Node Metastasis in Very Thin Invasive Melanomas.
    Br J Dermatol. 2023 Jun 8:ljad195. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. VERGARA IA, Stark MS
    One Step Closer to Improving Melanoma Diagnosis and Prognosis with Liquid Biopsies.
    Br J Dermatol. 2023 Jun 3:ljad185. doi: 10.1093.
    PubMed    
    
    
    May 2023
45. MUTO Y, Kambayashi Y, Kato H, Fukushima S, et al
    Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results.
    Br J Dermatol. 2023 May 27:ljad183. doi: 10.1093.
    PubMed    
    
    
    
46. 
    Two melanoma genes (MITF and MC1R) interact to cause different risks.
    Br J Dermatol. 2023;188:e44.
    PubMed    
    
    
    
47. POGORZELSKA-DYRBUS J, Szepietowski JC
    Melanoma cells in optical super-high magnification dermoscopy.
    Br J Dermatol. 2023 May 22:ljad168. doi: 10.1093.
    PubMed    
    
    
    
48. VAN LAAR R, Latif B, King S, Love C, et al
    Validation of microRNA Liquid Biopsy for Diagnosis and Risk Stratification of Invasive Cutaneous Melanoma.
    Br J Dermatol. 2023 May 5:ljad137. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
49. LALLAS A
    Which melanoma patients are at priority for monitoring to detect new primary melanoma?
    Br J Dermatol. 2023 Apr 17:ljad125. doi: 10.1093.
    PubMed    
    
    
    
50. IBRAHIM LS, Venables ZC, McPhail S, Levell NJ, et al
    Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019.
    Br J Dermatol. 2023 Apr 10:ljad117. doi: 10.1093.
    PubMed    
    
    
    
51. FUJISAWA Y, Namikawa K, Yoshino K, Kiniwa Y, et al
    Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases.
    Br J Dermatol. 2023 Apr 5:ljad114. doi: 10.1093.
    PubMed    
    
    
    March 2023
52. 
    Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
    Br J Dermatol. 2023;188:e29.
    PubMed    
    
    
    
53. ASCOTT A, van Bodegraven B, Vernon S, Orteu CH, et al
    The geographical variation of melanoma, basal and squamous cell carcinoma in England.
    Br J Dermatol. 2023 Mar 30:ljad100. doi: 10.1093.
    PubMed    
    
    
    
54. ARACTINGI S, Oules B
    Correcting 'false' warnings with new tools? An illustrative example.
    Br J Dermatol. 2023;188:452.
    PubMed    
    
    
    
55. BRUNO W
    Joint contribution of MC1R and MITF alleles to melanoma risk in the age of polygenic risk scores.
    Br J Dermatol. 2023 Mar 28:ljad097. doi: 10.1093.
    PubMed    
    
    
    
56. NI Y, Watts CG, Scolyer RA, Madronio C, et al
    Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
    Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093.
    PubMed    
    
    
    
57. WALLINGFORD CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, et al
    MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
    Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. OLSEN CM, Gordon LG, Carter SM, Whiteman DC, et al
    The ethical implications of opportunistic detection of melanoma in clinical care.
    Br J Dermatol. 2023 Mar 3:ljad055. doi: 10.1093.
    PubMed    
    
    
    
59. GHIASVAND R, Berge LAM, Andreassen BK, Green AC, et al
    Statin use and risk of cutaneous melanoma: A nationwide nested case-control study.
    Br J Dermatol. 2023 Mar 3:ljad057. doi: 10.1093.
    PubMed    
    
    
    February 2023
60. VAN BODEGRAVEN B, Vernon S, Eversfield C, Board R, et al
    "Get Data Out" Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
    Br J Dermatol. 2023 Feb 23:ljad033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. 
    Skin cancer and ultraviolet-radiation exposure in different jobs.
    Br J Dermatol. 2023;188:e22.
    PubMed    
    
    
    
62. SMITH H, Hussain W
    Is it time we changed the way we manage melanoma in situ of the trunk and limbs?
    Br J Dermatol. 2023 Feb 18:ljad031. doi: 10.1093.
    PubMed    
    
    
    
63. OLSEN CM, Pandeya N, Whiteman DC
    The rise in thick melanomas: can early detection reduce the burden?
    Br J Dermatol. 2023 Feb 15:ljad034. doi: 10.1093.
    PubMed    
    
    
    
64. POIZEAU F, Balusson F, Lemaitre F, Tron C, et al
    The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
    Br J Dermatol. 2023 Feb 10:ljac085. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2023
65. 
    Patients with melanoma and diabetes benefit from metformin treatment.
    Br J Dermatol. 2023;188:e5.
    PubMed    
    
    
    
66. BERTOLD C, Martel P, Passeron T, Bahadoran P, et al
    Pigmented demodicosis presenting as lentigo maligna diagnosed by reflectance confocal microscopy.
    Br J Dermatol. 2023;188:149-150.
    PubMed    
    
    
    
67. ZHOU L, Shao L, Gao S, Cui C, et al
    Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy.
    Br J Dermatol. 2023;188:112-121.
    PubMed     Abstract available
    
    
    
68. KRAKOWSKI I, Habel H, Nielsen K, Ingvar C, et al
    Association of metformin use and survival in patients with cutaneous melanoma and diabetes.
    Br J Dermatol. 2023;188:32-40.
    PubMed     Abstract available
    
    
    December 2022
69. PERRIER F, Robsahm TE, Ghiasvand R, Borch KB, et al
    No association between physical activity and primary melanoma thickness in a cohort of Norwegian women.
    Br J Dermatol. 2022 Dec 21:ljac136. doi: 10.1093.
    PubMed    
    
    
    November 2022
70. HE X, Shi H
    How does acral melanoma respond to immunotherapy?
    Br J Dermatol. 2022 Nov 10:ljac035. doi: 10.1093.
    PubMed    
    
    
    August 2022
71. KAWSAR A, Edwards C, Patel P, Heywood RM, et al
    Checkpoint inhibitor associated bullous cutaneous immune related adverse events: a multi-centre observational study.
    Br J Dermatol. 2022 Aug 17. doi: 10.1111/bjd.21836.
    PubMed     Abstract available
    
    
    
72. BELL KJL, Nijsten T
    Melanoma overdiagnosis: why it matters and what can be done about it.
    Br J Dermatol. 2022 Aug 5. doi: 10.1111/bjd.21750.
    PubMed    
    
    
    July 2022
73. NIKOLAOU V, Apalla Z, Carrera C, Fattore D, et al
    Clinical associations and classification of immune checkpoint inhibitors-induced cutaneous toxicities: A multicentric study from the EADV-Task Force of Dermatology for Cancer Patients.
    Br J Dermatol. 2022 Jul 21. doi: 10.1111/bjd.21781.
    PubMed     Abstract available
    
    
    June 2022
74. SANTANDREA G, Valli R, Ragazzi M, Castagnetti F, et al
    Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role.
    Br J Dermatol. 2022 Jun 28. doi: 10.1111/bjd.21715.
    PubMed    
    
    
    
75. CALBET-LLOPART N, Combalia M, Kiroglu A, Potrony M, et al
    Common genetic variants associated with melanoma risk or naevus count in wild-type MC1R melanoma patients.
    Br J Dermatol. 2022 Jun 14. doi: 10.1111/bjd.21707.
    PubMed     Abstract available
    
    
    May 2022
76. RICCI F, Abeni D
    Heterogeneity of reports about the impact of the COVID-19 pandemic on melanoma diagnosis.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21598.
    PubMed    
    
    
    
77. OLSEN CM
    International surveillance of trends in melanoma survival: the impact of morphology.
    Br J Dermatol. 2022 May 24. doi: 10.1111/bjd.21651.
    PubMed    
    
    
    
78. KAMMINGA NCW, van der Veldt AAM, Joosen MCW, de Joode K, et al
    Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.
    Br J Dermatol. 2022 May 21. doi: 10.1111/bjd.21670.
    PubMed     Abstract available
    
    
    
79. WHITEMAN DC, Olsen CM, MacGregor S, Law MH, et al
    The effect of screening on melanoma incidence and biopsy rates.
    Br J Dermatol. 2022 May 9. doi: 10.1111/bjd.21649.
    PubMed     Abstract available
    
    
    
80. SCHUMMER P, Schilling B
    How representative are data from global trials on programmed death-1 blockade in melanoma?
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21621.
    PubMed    
    
    
    
81. CARRERA C, Podlipnik S
    Does acral melanoma need a distinctive prognostic staging system?
    Br J Dermatol. 2022 May 3. doi: 10.1111/bjd.21585.
    PubMed    
    
    
    
82. WAKKEE M
    Polygenic risk scores for melanoma: a stepwise process towards clinical implementation.
    Br J Dermatol. 2022;186:768.
    PubMed    
    
    
    April 2022
83. HARVIMA IT, Harvima RJ
    Survival from cutaneous malignant melanoma is improving, but is it because of a trend in decreasing melanoma thickness or the advent of new 'revolutionary' therapeutics?
    Br J Dermatol. 2022 Apr 12. doi: 10.1111/bjd.21583.
    PubMed    
    
    
    March 2022
84. KATO J, Namikawa K, Uehara J, Nomura M, et al
    Prognoses of melanoma patients who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: A multicenter retrospective study.
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21276.
    PubMed    
    
    
    
85. DI CARLO V, Stiller CA, Eisemann N, Bordoni A, et al
    Does the morphology of cutaneous melanoma help explain the international differences in survival? Results from 1,578,482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
    Br J Dermatol. 2022 Mar 29. doi: 10.1111/bjd.21274.
    PubMed     Abstract available
    
    
    
86. KURTANSKY NR, Manci RN, Bello DM, Adamson AS, et al
    Risk of non-acral cutaneous melanoma after the diagnosis of acral melanoma.
    Br J Dermatol. 2022 Mar 23. doi: 10.1111/bjd.21251.
    PubMed    
    
    
    
87. BAI X, Shoushtari AN, Betof Warner A, Si L, et al
    Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study.
    Br J Dermatol. 2022 Mar 16. doi: 10.1111/bjd.21241.
    PubMed     Abstract available
    
    
    
88. ZAMAGNI F, Bucchi L, Mancini S, Crocetti E, et al
    The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.21051.
    PubMed     Abstract available
    
    
    
89. PARAGH G
    Epidermal melanoma prognostic factors: a link to paracrine transforming growth factor-beta signalling.
    Br J Dermatol. 2022 Mar 2. doi: 10.1111/bjd.20981.
    PubMed    
    
    
    February 2022
90. SANGERS TE, Wakkee M, Kramer-Noels EC, Nijsten T, et al
    Limited impact of COVID-19 related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumor characteristics: A nationwide pathology registry analysis.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21050.
    PubMed     Abstract available
    
    
    
91. EDEN M, Hainsworth R, Gordon LG, Epton T, et al
    Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.
    Br J Dermatol. 2022 Feb 10. doi: 10.1111/bjd.21046.
    PubMed     Abstract available
    
    
    January 2022
92. WEI X, Wu D, Chen Y, Li H, et al
    Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21026.
    PubMed     Abstract available
    
    
    
93. SEMSARIAN CR, Ma T, Nickel B, Scolyer RA, et al
    Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
    Br J Dermatol. 2022 Jan 10. doi: 10.1111/bjd.21010.
    PubMed    
    
    
    December 2021
94. STEINBERG J, Iles MM, Lee JY, Wang X, et al
    Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts.
    Br J Dermatol. 2021 Dec 18. doi: 10.1111/bjd.20956.
    PubMed     Abstract available
    
    
    November 2021
95. SUN MD, Kentley J, Mehta P, Duzsa S, et al
    Accuracy of commercially available smartphone applications for the detection of melanoma.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20903.
    PubMed     Abstract available
    
    
    
96. COSGAREA I, McConnell AT, Ewen T, Tang D, et al
    Melanoma secretion of TGFbeta-2 leads to loss of epidermal AMBRA1 threatening epidermal integrity and facilitating tumour ulceration.
    Br J Dermatol. 2021 Nov 13. doi: 10.1111/bjd.20889.
    PubMed     Abstract available
    
    
    
97. MAEDA T, Hiura A, Uehara J, Toyoshima R, et al
    Early tumor response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20879.
    PubMed     Abstract available
    
    
    
98. CAMARA NOS
    Do the gut and skin microbiomes share thoughts on melanoma development?
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20811.
    PubMed    
    
    
    October 2021
99. HAW WY, Al-Janabi A, Arents BWM, Asfour L, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines.
    Br J Dermatol. 2021;185:736-744.
    PubMed     Abstract available
    
    
    September 2021
100. FROMME JE, Zigrino P
     Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor.
     Br J Dermatol. 2021 Sep 30. doi: 10.1111/bjd.20756.
     PubMed    
     
     
     
101. KIM J, Choi H
     The mucin protein MUCL1 regulates melanogenesis and melanoma genes in a manner dependent on threonine content.
     Br J Dermatol. 2021 Sep 21. doi: 10.1111/bjd.20761.
     PubMed     Abstract available
     
     
     
102. MAEDA T, Hiura A, Uehara J, Toyoshima R, et al
     Combined carboplatin and paclitaxel therapy improves overall survival in patients with nivolumab-resistant acral and mucosal melanoma.
     Br J Dermatol. 2021 Sep 12. doi: 10.1111/bjd.20758.
     PubMed     Abstract available
     
     
     
103. LALLAS A, Moscarella E, Kittler H, Longo C, et al
     Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna.
     Br J Dermatol. 2021;185:675-677.
     PubMed    
     
     
     August 2021
104. CUST AE
     Strengthening melanoma prevention and early detection among people with type 2 diabetes.
     Br J Dermatol. 2021 Aug 18. doi: 10.1111/bjd.20633.
     PubMed    
     
     
     
105. TSAO H
     Melanoma medicine in the new millennium.
     Br J Dermatol. 2021;185:239-240.
     PubMed    
     
     
     July 2021
106. DATZMANN T, Schoffer O, Meier F, Seidler A, et al
     Patients benefit from participating in the German skin cancer screening program? A large cohort study based on administrative data.
     Br J Dermatol. 2021 Jul 21. doi: 10.1111/bjd.20658.
     PubMed     Abstract available
     
     
     
107. STOER NC, Botteri E, Busund M, Ghiasvand R, et al
     Menopausal hormone therapy and risk of melanoma: a population-based cohort study.
     Br J Dermatol. 2021 Jul 13. doi: 10.1111/bjd.20640.
     PubMed     Abstract available
     
     
     
108. SCATOLINI M, Patel A, Grosso E, Mello-Grand M, et al
     GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma.
     Br J Dermatol. 2021 Jul 8. doi: 10.1111/bjd.20629.
     PubMed     Abstract available
     
     
     
109. VITALI F, Colucci R, Di Paola M, Pindo M, et al
     Early melanoma invasivity correlates with gut fungal and bacterial profiles.
     Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20626.
     PubMed     Abstract available
     
     
     June 2021
110. ALTAYEB A, Dawood S, Atwan A, Mills C, et al
     Teledermoscopy: A Helpful Detection Tool for Amelanotic and Hypomelanotic Melanoma.
     Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20609.
     PubMed     Abstract available
     
     
     
111. HARGADON KM
     The Role of Interferons in Melanoma Resistance to Immune Checkpoint Blockade: Mechanisms of Escape and Therapeutic Implications.
     Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20608.
     PubMed     Abstract available
     
     
     
112. WIGGINS J, Polsky D
     Melanoma origins: data from early-stage tumours supports de novo and naevus-associated melanomas as distinct subtypes.
     Br J Dermatol. 2021 Jun 11. doi: 10.1111/bjd.20396.
     PubMed    
     
     
     
113. GUHAN S, Klebanov N, Tsao H
     Melanoma genomics: a state-of-the-art review of practical clinical applications.
     Br J Dermatol. 2021 Jun 6. doi: 10.1111/bjd.20421.
     PubMed     Abstract available
     
     
     
114. GAO JM, Garioch JJ, Fadhil M, Tan E, et al
     Planning slow Mohs excision margins for lentigo maligna: a retrospective nonrandomized cohort study comparing reflectance confocal microscopy margin mapping vs. visual inspection with dermoscopy.
     Br J Dermatol. 2021;184:1182-1183.
     PubMed    
     
     
     May 2021
115. YEH I, Bastian BC
     Melanoma pathology: new approaches and classification.
     Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20427.
     PubMed     Abstract available
     
     
     
116. MAHAMAT-SALEH Y
     Is consumption of citrus associated with a higher risk of melanoma?
     Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20408.
     PubMed    
     
     
     
117. CLAESON M, Baade P, Marchetti M, Brown S, et al
     Comparative performance of predictors of death from thin (
     Br J Dermatol. 2021 May 12. doi: 10.1111/bjd.20480.
     PubMed     Abstract available
     
     
     
118. CHEN Y, Andre M, Adhikari K, Blin M, et al
     A GWAS identifies novel gene associations with facial skin wrinkling and mole count in Latin-Americans.
     Br J Dermatol. 2021 May 6. doi: 10.1111/bjd.20436.
     PubMed     Abstract available
     
     
     April 2021
119. DOUSSET L, Martins C, Jacquemin C, Amico S, et al
     Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with high frequency of melanoma-infiltrating CXCR3(+) resident memory CD8(+) T cells and multiple chemokine pathways.
     Br J Dermatol. 2021 Apr 24. doi: 10.1111/bjd.20405.
     PubMed     Abstract available
     
     
     
120. DESSINIOTI C, Geller AC, Whiteman DC, Garbe C, et al
     Not all melanomas are created equal: A review and call for more research into nodular melanoma.
     Br J Dermatol. 2021 Apr 16. doi: 10.1111/bjd.20388.
     PubMed     Abstract available
     
     
     
121. KITTLER H
     Total body photography for secondary prevention of melanoma.
     Br J Dermatol. 2021 Apr 6. doi: 10.1111/bjd.20058.
     PubMed    
     
     
     
122. AGRAWAL R, Tso S, Eltigani EA, Busam KJ, et al
     PRAME immunohistochemistry as an adjunct in the diagnosis of paucicellular lentigo maligna in a young man.
     Br J Dermatol. 2021;184:e122.
     PubMed    
     
     
     March 2021
123. MARLEY AR, Li M, Champion VL, Song Y, et al
     The Association between Citrus Consumption and Melanoma Risk in the UK Biobank.
     Br J Dermatol. 2021 Mar 30. doi: 10.1111/bjd.19896.
     PubMed     Abstract available
     
     
     
124. GHIASVAND R
     Divergent pathways for melanoma: what is the role of genetics?
     Br J Dermatol. 2021 Mar 25. doi: 10.1111/bjd.19887.
     PubMed    
     
     
     
125. PEREZ M, Chakraborty A, Lau LS, Mohammed NBB, et al
     Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target.
     Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19891.
     PubMed     Abstract available
     
     
     
126. EL SHAROUNI MA, Varey AHR, Witkamp AJ, Ahmed T, et al
     Predicting sentinel node positivity in melanoma patients: external validation of a risk-prediction calculator (the MIA nomogram) using a large European population-based patient cohort.
     Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19895.
     PubMed     Abstract available
     
     
     February 2021
127. WOLNER ZJ, Flowers NI, Yushak ML, Chen SC, et al
     Exploring the melanoma survivorship experience: a qualitative study.
     Br J Dermatol. 2021 Feb 5. doi: 10.1111/bjd.19868.
     PubMed     Abstract available
     
     
     January 2021
128. DESSINIOTI C, Geller AC, Stergiopoulou A, Dimou N, et al
     A multicenter study of nevus-associated melanoma versus de novo melanoma, tumor thickness and body site differences.
     Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19819.
     PubMed     Abstract available
     
     
     
129. NAGORE E, Martinez-Garcia MA, Gomez-Olivas JD, Manrique-Silva E, et al
     Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: An observational multi-centric study in 443 patients with melanoma.
     Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19813.
     PubMed     Abstract available
     
     
     
130. GAULT A, Anderson AE, Plummer R, Stewart C, et al
     Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
     Br J Dermatol. 2021 Jan 4. doi: 10.1111/bjd.19750.
     PubMed     Abstract available
     
     
     December 2020
131. TOLAND AE
     The influence of sex, age and sunlight exposure on mutational processes in melanoma.
     Br J Dermatol. 2020 Dec 28. doi: 10.1111/bjd.19336.
     PubMed    
     
     
     
132. JI-XU A, Dinnes J, Matin RN
     Total Body Photography for the Diagnosis of Cutaneous Melanoma in Adults: A Systematic Review and Meta-Analysis.
     Br J Dermatol. 2020 Dec 28. doi: 10.1111/bjd.19759.
     PubMed     Abstract available
     
     
     
133. VUONG K, Armstrong BK, Espinoza D, Hopper JL, et al
     An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study.
     Br J Dermatol. 2020 Dec 3. doi: 10.1111/bjd.19706.
     PubMed     Abstract available
     
     
     
134. LASKAR R, Ferreiro-Iglesias A, Bishop DT, Iles MM, et al
     Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.
     Br J Dermatol. 2020 Dec 3. doi: 10.1111/bjd.19705.
     PubMed     Abstract available
     
     
     November 2020
135. NAKAMURA M, Obayashi M, Yoshimitsu M, Kato H, et al
     Comparative whole-exome sequencing of an ultra-late recurrent malignant melanoma.
     Br J Dermatol. 2020 Nov 18. doi: 10.1111/bjd.19680.
     PubMed     Abstract available
     
     
     October 2020
136. CHARVET E, Kramkimel N, Chaplain L, Gantzer A, et al
     Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-PD-1 monoclonal antibodies.
     Br J Dermatol. 2020 Oct 24. doi: 10.1111/bjd.19629.
     PubMed     Abstract available
     
     
     
137. GHIASVAND R, Khosrotehrani K, Hughes MCB, von Schuckmann LA, et al
     Patient age and risk of recurrence of primary melanoma at high risk of spread.
     Br J Dermatol. 2020 Oct 14. doi: 10.1111/bjd.19601.
     PubMed     Abstract available
     
     
     
138. MINIOTTI M, Ribero S, Leombruni P
     Targeting fear of recurrence: the advantages of assessing psychosocial attributes and psychological dispositions.
     Br J Dermatol. 2020;183:789-790.
     PubMed    
     
     
     
139. HAUGAARD JH, Egeberg A
     Do we need to fear methotrexate?
     Br J Dermatol. 2020;183:608-609.
     PubMed    
     
     
     September 2020
140. BLANKENSTEIN SA, van Akkooi ACJ
     Broadening indications for neoadjuvant immunotherapy.
     Br J Dermatol. 2020;183:421-422.
     PubMed    
     
     
     August 2020
141. NAPOLITANO M, Caiazzo G, Fabbrocini G, Balato A, et al
     Increased expression of IL-23A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment.
     Br J Dermatol. 2020 Aug 6. doi: 10.1111/bjd.19464.
     PubMed     Abstract available
     
     
     July 2020
142. SHEEN YS, Chu CY
     Co-occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma.
     Br J Dermatol. 2020 Jul 22. doi: 10.1111/bjd.19416.
     PubMed    
     
     
     
143. ALFONSO JH, Martinsen JI, Weiderpass E, Pukkala E, et al
     Occupation and cutaneous melanoma: a 45-year historical cohort study of 14.9 million people in five Nordic countries.
     Br J Dermatol. 2020 Jul 6. doi: 10.1111/bjd.19379.
     PubMed     Abstract available
     
     
     May 2020
144. KARAKOUSIS G
     Immune checkpoint blockade: an urgent call for biomarkers to help guide treatment.
     Br J Dermatol. 2020;182:1085-1086.
     PubMed    
     
     
     March 2020
145. ROBINSON JK, Abou-El-Seoud D, Reavy R, Turrisi R, et al
     Persistence of partner-assisted skin self-examination supported by "being in this together": a randomized trial.
     Br J Dermatol. 2020 Mar 28. doi: 10.1111/bjd.19048.
     PubMed     Abstract available
     
     
     December 2019
146. HARTMAN RI, Xue Y, Singer S, Markossian TW, et al
     Modeling the Value of Risk Stratified Skin Cancer Screening of Asymptomatic Patients by Dermatologists.
     Br J Dermatol. 2019 Dec 22. doi: 10.1111/bjd.18816.
     PubMed     Abstract available
     
     
     March 2019
147. ROBERTS MR, Asgari MM, Toland AE
     Genome-wide association studies and polygenic risk scores for skin cancer: clinically useful yet?
     Br J Dermatol. 2019 Mar 25. doi: 10.1111/bjd.17917.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.